Ramses Vega, MD
Internal Medicine · Miami, FLNPI 1760429716
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Sunovion Pharmaceuticals Inc. at 42.7% of the total. Reporting peaked in 2019 at $426 and has fallen 76.4% since, to $100 in 2025.
Across 54 payments — averaging $22.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$518
- AstraZeneca$108
- Bayer$89
- Amgen$79
- Johnson & Johnson$67
- Novo Nordisk$66
- plus $287 from 11 others
Across 563 payments — averaging $7780.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beigene, Ltd.$1.3M
- Genentech, Inc.$884K
- AstraZeneca$682K
- Bausch Health US, LLC$610K
- Janssen Research & Development, LLC$245K
- Astrazeneca UK Limited$187K
- plus $470K from 11 others
What the payments were for
- Food & beverage$1,214100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 22 | $518 |
| AstraZeneca | 3 | $108 |
| Bayer | 4 | $89 |
| Amgen(2 entities) | 4 | $79 |
| Johnson & Johnson | 4 | $67 |
| Novo Nordisk | 3 | $66 |
| Astellas Pharma US Inc | 3 | $58 |
| Mylan Specialty L.p. | 2 | $42 |
| Smith+Nephew | 1 | $38 |
| Neurocrine Biosciences, Inc. | 1 | $32 |
| Merck | 1 | $22 |
| Novartis | 1 | $21 |
| GSK | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LONHALA MAGNAIR$117
How this compares
$1,214 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 26 | $32,952 |
| EliquisApixaban | 46 | $27,299 |
| XareltoRivaroxaban | 45 | $25,155 |
| OzempicSemaglutide | 15 | $14,718 |
| FarxigaDapagliflozin Propanediol | 18 | $12,419 |
| Celecoxib | 55 | $2,125 |
| Acetazolamide | 49 | $2,091 |
| Levothyroxine Sodium | 138 | $1,566 |
| Bisoprolol Fumarate | 72 | $1,533 |
| Acetazolamide ErAcetazolamide | 19 | $1,501 |
| Duloxetine Hcl | 34 | $1,249 |
| Gabapentin | 114 | $1,133 |
| Atorvastatin Calcium | 115 | $1,087 |
| Bumetanide | 26 | $1,059 |
| Fluticasone Propionate | 64 | $866 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $21 | $32,95226 claims |
| Johnson & JohnsonXarelto | $67 | $25,15545 claims |
| Novo NordiskOzempic | $66 | $14,71815 claims |
| AstraZenecaFarxiga | $108 | $12,41918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Miami
- Haytham ElgammalMiami$2.2M
- Richard AguilarMiami$239K
- Maria Delgado LelievreMiami$80K
- Marlow HernandezMiami$58K
- Steven CohnMiami$47K
- Joseph PiperatoMiami$45K
- Simon AbelsonMiami$44K
- Joel Brooks TamayoMiami$42K
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.